Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – In an organic compound
Reexamination Certificate
2007-02-06
2007-02-06
Jones, Dameron L. (Department: 1618)
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
In an organic compound
C424S001110, C424S001650, C424S001850, C424S001890, C424S009300, C424S009370, C544S224000, C514S247000, C514S248000
Reexamination Certificate
active
10659747
ABSTRACT:
Radiolabeled epidermal growth factor receptor tyrosine kinase (EGFR-TK) irreversible inhibitors and their use as biomarkers for medicinal radioimaging such as Positron Emission Tomography (PET) and Single Photon Emission Computed Tomography (SPECT) and as radiopharmaceuticals for radiotherapy are disclosed.
REFERENCES:
patent: 5760041 (1998-06-01), Wissner et al.
patent: 6126917 (2000-10-01), Mishani et al.
patent: 6127374 (2000-10-01), Bridges
patent: 6153617 (2000-11-01), Bridges
patent: 6251912 (2001-06-01), Wissner et al.
patent: 6562319 (2003-05-01), Mishani et al.
patent: 2002/0128553 (2002-09-01), Mishani et al.
patent: 2004/0265228 (2004-12-01), Levitzki et al.
patent: WO 99/09016 (1999-02-01), None
patent: WO 02/073235 (2002-09-01), None
patent: WO 2004/046101 (2004-03-01), None
patent: WO 2005/023315 (2005-03-01), None
Smaill et al. “Tyrosine Kinase Inhibitors. 17. Irreversible Inhibitors of the Epidermal Growth Factor Receptor: 4-(Phenylamino)Quinazoline- and 4-(Phenylamino)Pyrido[3,2-d]Pyrimidine-6-Acrylamides Bearing Additional Solubilizing Functions”, Journal of Medicinal Chemistry, 43: 1380-1397, 2000. Compound 18, 25-27, Table 1.
Smaill et al. “Tyrosine Kinase Inhibitors. 15. 4-(Phenylamino)Quiazoline and 4-(Phenylamino)Pyrido[d]Pyrimidine Acrylamides as Irreversible Inhibitors of the ATP Binding Site of the Epidermal Growth Factor Receptor”, Journal of Medicinal Chemistry, 42: 1802-1815, 1999.
Mishani et al. “Carbon-11 Labeling of -Dimethylamino-But-2-Enoic Acid [4-(Phenylamino)-Quinazolin-6-Yl]-Amides, A New Class of EGFR Irreversible Inhibitors”, Journal of Labelled Compounds and Radiopharmaceuticals, 46(S1): S2, 2003. Abstract.
Ortu et al. “Labeled EGFR-TK Irreversible Inhibitor (ML03) In Vitro and In Vivo Properties, Potential as Pet Biomarker for Cancer and Feasibility as Anticancer Drug”, International Journal of Cancer, 101: 360-370, 2002. Conclusion, p. 361, Col.1,§ 1, Fig.1.
Johnström et al. “Synthesis of [Methoxy-1lC]PD153035, A Selective EGF Receptor Tyrosine Kinase Inhibitor”, Journal of Labbelled Compounds and Radiopharmaceuticals, XLI: 623-629, 1998. p. 627, Fig.3.
Mishani et al. “Novel Carbon-11 Labeled 4-Dimethylamino-But-2-Enoic Acid [4-(Phenylamino)-Quinazoline-6-Yl]-Amides: Potential PET Bioprobes for Molecular Imaging of EGFR-Positive Tumors”, Nuclear Medicine and Biology, 31(4): 469-476, 2004. P.474, Col.2, § 4—p. 475, Figs.2, 3.
Ben-David Iris
Levitzki Alexander
Mishani Eyal
Ortu Giuseppina
Rozen Yulia
Hadasit Medical Research Services and Development Ltd.
Jones Dameron L.
Yissum Research Development Company of the Hebrew University of
LandOfFree
Radiolabeled irreversible inhibitors of epidermal growth... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Radiolabeled irreversible inhibitors of epidermal growth..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radiolabeled irreversible inhibitors of epidermal growth... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3820353